PIERLUIGI BERTORA
Assistant professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Pierluigi Bertora is an Assistant Professor at the Università degli Studi di Milano, Italy. His research focuses on cognitive impairment in stroke patients, exploring its association with neuropsychiatric and functional features. He has contributed to studies on the predictive value of neuropsychological tests in the context of cerebrovascular diseases.
Articles (4)
BACKGROUND: Some patients with stroke have prestroke cognitive impairment (pre-SCI), but its etiology is not clear. The aim of this cross-sectional study was to assess the frequency of pre-SCI and its association with premorbid neuropsychiatric, functional, and neuroimaging features. METHODS: Patients hospitalized in stroke unit with an informant who could complete IQCODE (Informant Questionnaire for Cognitive Decline in the Elderly) were included. Pre-SCI was diagnosed if the IQCODE score was >3.3. Prestroke assessment also included NPI-Q (Neuropsychiatric Inventory Questionnaire), the basic Activities of Daily Living and Instrumental Activities of Daily Living scales, and the Clinical Dementia Rating scale. A multivariate logistic regression model was used to evaluate the association of pre-SCI with age, sex, education, arterial hypertension, atrial fibrillation, white matter lesions, cerebral microbleeds, and pathological medial temporal lobe atrophy. RESULTS: IQCODE was available in 474 of 520 patients (91.2%; 45% women; mean age 75.5±13.3 years). Pre-SCI had a prevalence of 32.5% and was associated with prestroke NPI-Q (pre-SCI absent versus present, 1.7±2.3 versus 5.5±4.9; P <0.001), Activities of Daily Living scale (0.3±0.8 versus 1.8±1.9; P <0.001), Instrumental Activities of Daily Living scale (0.6±1.3 versus 3.8±4.0; P <0.001), and Clinical Dementia Rating scale score (0.7±1.7 versus 7.2±6.2; P <0.001). In the 271 patients with a magnetic resonance imaging available, the multivariate logistic regression showed that age (odds ratio [OR], 1.05 [95% CI, 1.62–9.73]), white matter lesions (OR, 1.26 [95% CI, 1.003–1.58]), and a pathological medial temporal lobe atrophy score (OR, 3.97 [95% CI, 1.62–9.73]) were independently associated with pre-SCI. In the 218 patients with ischemic stroke, white matter lesions (OR, 1.34 [95% CI, 1.04–1.72]) and medial temporal lobe atrophy (OR, 3.56 [95% CI, 1.38–9.19]), but not age, were associated with pre-SCI. CONCLUSIONS: One-third of patients admitted to a stroke unit have pre-SCI that is associated with preexisting neuropsychiatric symptoms and functional performance. White matter lesions and medial temporal lobe atrophy are associated with pre-SCI, suggesting that both small vessel disease and neurodegeneration might be involved in its etiology.
Year:
2024
Background The efficacy and safety of statins for secondary prevention in patients who have experienced a cardioembolic stroke are not well-defined. However, previous observational data reported hyperlipidemia as a risk factor for both ischemic and bleeding complications in patients with AF and previous stroke. Based on these premises, we conducted a sub-analysis of the RAF and RAF-NOAC studies to evaluate the efficacy and safety of statins in secondary prevention in patients with acute ischemic stroke and AF. Methods We combined patient data from the RAF and RAF-NOAC studies, prospective observational studies conducted across Stroke Units in Europe, the United States, and Asia from January 2012 to June 2016. We included consecutive patients with AF who suffered an acute ischemic stroke with a follow-up of 90 days. Our outcomes were the combined endpoint, including stroke, transient ischemic attack, systemic embolism, symptomatic intracerebral hemorrhage, and major extracranial bleeding. Furthermore, both ischemic and hemorrhagic outcomes were evaluated separately. Results A total of 1.742 patients were included (46% male), and 898 (52%) received statins after the index event. At multivariable analysis, statin use was statistically associated with age (OR 0.92, 95% CI 0.97 - 0.99, p = 0.001), male sex (OR 1.35, 95% CI 1.07 - 1.70, p = 0.013), anticoagulation (OR 2.53, 95% CI 1.90 - 3.36, p <0.0001), hyperlipidemia (OR 5.52, 95% CI 4.28 - 7.12, p <0.0001), paroxysmal AF (OR 1.40, 95% CI 1.12 - 1.75, p = 0.003), leukoaraiosis (OR 1.39, 95% CI 1.11 - 1.75, p = 0.004) and heart failure (OR 0.72, 95% CI 0.53 - 0.98, p = 0.034). Statin use was not associated with the combined outcome event (OR 0,81, 95% CI 0,56 – 1,19, p = 0.286) and ischemic outcome event (OR 1,13, 95% CI 0,71 – 1,82, p = 0.604) while was associated with a lower risk of hemorrhagic outcome event (OR 0,49, 95% CI 0,27 – 0,88, p = 0.016). Conclusions Our data show that statins seem to protect against global bleeding events in cardioembolic stroke patients; this may be due to the pleiotropic effect of statins. More data are warranted to confirm these findings.
Year:
2024
Year:
2022
Year:
2020
Collaborators (36)
Simona Sacco
Full Professor of Neurology - Head of the Clinical Neurology Unit
University of L'Aquila
Danilo Toni
Full Professor of Neurology
Sapienza University
Alessandro Pezzini
Associate Professor of Neurology
University of Parma
Walter Ageno
Associate Professor
University of Insubria
Davide Strambo
-
George Ntaios
Professor of Internal Medicine
University of Thessaly
Sung Il Sohn
Professor
Keimyung University Dongsan Medical Center
Theodoros Karapanayiotides
Associate Professor
Aristotle University of Thessaloniki
Georgios Tsivgoulis
-
Piergiorgio Lochner
Head of Neurointensive Care Unit Unit and Neurosonology Lab
Saarland University
Patrik Michel
Associate Professor
Lausanne University Hospital
Eugenia Rota
Chief
-
Jukka Putaala
-
Maria Kosmidou
Ass Professor
Aristotle University of Thessaloniki
Brian Mac Grory
Assistant Professor
Duke University School of Medicine
Azmil H Abdul-Rahim
University of Glasgow
Gian Marco De Marchis
Head of Personal Board
University Hospital Basel
MARINA DIOMEDI
Associate Professor, Tor Vergata University
University of Rome Tor Vergata
Laetitia Yperzeele
Antwerp University Hospital
Leonardo Pantoni
-
Stefan Engelter
Chair Department Rehabilitation & Neurology and Head of Stroke Treatment Pathyway
-
Sotirios Giannopoulos
Professor fo Neurology
National and Kapodistrian University of Athens
Lina Palaiodimou
National and Kapodistrian University of Athens
Jesse Dawson
Professor of Stroke Medicine
University of Glasgow
Yuriy Flomin
Professor
ukraine; shupyk national healthcare university of ukraine
Turgut Tatlisumak
Professor
Göteborgs Universitet
Isabella Canavero
Fondazione IRCCS Istituto Neurologico Carlo Besta
Daniel Strbian
-
PANAGIOTIS HALVATSIOTIS
Associate Professor
National and Kapodistrian University of Athens - Faculty of Medicine
Maurizio Paciaroni
Docenti di ruolo di IIa fascia
University of Ferrara
Konstantinos Vadikolias
Professor
Democritus University of Thrace
Maurizio Acampa
University of Siena
David Seiffge
-
Andrea Morotti
-
Alexandros Polymeris
Attending Neurologist
University Hospital Basel
Manuel Cappellari
-
Make your next move.
Prepare your application
Review drafts before you send them.